Cape Town, South Africa, November 9 (ots/PRNewswire) -
- Technology Transfer Creates Sustainable Solution to Treat One of
the World's Oldest and Deadliest Diseases
During the annual meeting of the International Union Against
Tuberculosis and Lung Disease (IUATLD), The Lilly MDR-TB Partnership
brought together experts to highlight the battle against
multidrug-resistant tuberculosis (MDR-TB) in South Africa as a model
for the work being done by The Partnership around the world. South
Africa is one of the highest-burden MDR- TB countries.
The Lilly MDR-TB Partnership -- a public-private initiative of 14
organizations focused on stopping the spread of MDR-TB and ultimately
conquering the disease -- is transferring manufacturing know-how to
technology partners around the world. The technology transfer partner
in South Africa, Aspen Pharmacare, sold its first batch of
cycloserine to Botswana in 2006 and is now producing cycloserine in a
brand new facility in Port Elizabeth, South Africa, that has a
capacity in excess of 4 billion tablets and capsules per year.
Cycloserine is a Lilly antibiotic that is instrumental in the
treatment of second-line tuberculosis, or MDR-TB.
Aspen has also now begun construction of a facility at the Port
Elizabeth site to produce vials of capreomycin, another critical
medicine in the fight against second-line tuberculosis, and is
expected to produce this medicine at the facility in early 2009.
Capreomycin was developed by Eli Lilly and Company several years ago.
"The ability to manufacture cycloserine locally is essential to
treating the plight of multidrug resistance in South Africa," said
Mr. Stavros Nicolaou, Executive Director of Aspen Pharmacare. "This
initiative allows us to directly address this highly contagious
disease, which has a tremendous impact on the health of our country
and the entire African continent."
Aspen Pharmacare works closely with the World Health Organization
(WHO) to supply medicine to countries approved by the WHO Green Light
Committee (GLC). The GLC helps countries gain access to high-quality,
second-line anti-TB medicines so they can provide treatment for
people with MDR-TB in line with WHO guidelines.
In addition to the transfer of technology, The Lilly MDR-TB
Partnership enhances access to medicines, trains doctors and nurses,
raises awareness, promotes prevention, supports communities,
advocates on behalf of patients and conducts early-stage drug
"The Lilly Partnership initiatives all have one thing in common --
improved care for some of the world's most vulnerable people," said
Dr. Patrizia Carlevaro, Head of the International Aid Unit for Eli
Lilly and Company. "Through initiatives that create immediate, yet
sustainable solutions, our shared goal is to contain and someday
conquer this deadly disease."
Lilly will host a Satellite Symposium, "The Lilly MDR-TB
Partnership: Coming Together to Fight TB Resistance," at the IUATLD
meeting. The Symposium is focused on sharing best practices and
insights about this public-private initiative, which is now in its
fifth year. The IUATLD, composed of 127 member countries, has
provided technical assistance, education and research promoting lung
health in low- and middle-income countries for nearly a century.
The Lilly MDR-TB Partnership business model, including its unique
transfer of technology, is making such an impact that it is now being
taught as part of public policy course work at INSEAD in Paris,
France, and soon will be taught at Harvard and Columbia Universities
in the U.S.
About the Lilly MDR-TB Partnership
The Lilly MDR-TB Partnership was created to confront
multidrug-resistant tuberculosis, a disease so daunting that no
single organization can fight it alone. Since 2003, this
public-private initiative, mobilizing 14 partners on five continents,
has worked together to share expertise in the quest to contain and
conquer one of the world's oldest diseases. The Partnership's
multi-pronged approach includes: community support and patient
advocacy; treatment, training and surveillance; transferring
technology; research; and awareness and prevention. Additional
information about The Lilly MDR-TB Partnership is available at
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20071109/CLF001LOGO )
Web site: http://www.lillymdr-tb.com
ots Originaltext: Eli Lilly and Company
Im Internet recherchierbar: http://www.presseportal.ch
Christine Van Marter, Eli Lilly and Company, +1-317-554-7923. Photo:
http://www.newscom.com/cgi-bin/prnh/20071109/CLF001LOGO , PRN Photo